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Abstract
Within the HIV clinical trial field, there are gaps in existing ethical regulations in relation to
post-trial care. There is need to develop post-trial care guidelines that are flexible and sensi-
tive to local contexts and to the specific needs of different groups of participants, particularly
in low income contexts. Evidence regarding HIV trial closure and post-trial care is required
to underpin the development of appropriate policies in this area. This article reports research
from Uganda that develops a new model of ‘Facilitated Transition’ to conceptualize the tran-
sition process of HIV positive trial participants from ‘research’ to ‘usual care’ health facilities
after trial conclusion. This was a qualitative grounded theory study that included 21 adult
HIV positive post-trial participants and 22 research staff, undertaken between October 2014
and August 2015. The findings showed that trial closure is a complex process for HIV posi-
tive participants which includes three phases: the pre-closure, trial-closure, and post-trial
phases. The model highlights a range of different needs of research participants and sug-
gests specific and person-centred interventions that can be delivered at different phases
with the aim of improving health outcomes and experiences for trial participants in low
income settings during trial closure. Further research needs to be done to verify the model in
other contexts and for other conditions.
1. Introduction
In low income settings such as Uganda, it is a reality that most aspects of healthcare provided
in a clinical trial context (in research clinics) is usually significantly better than public sector
provision [1, 2]. Once withdrawn from such care at trial closure, trial participants can experi-
ence feelings of loss and other negative effects [3, 4]. Studies have shown that these negative
effects include issues such as psychological stress related to loss of quality care and loss of
material benefits, worries about how to access care after trial exit, challenges associated with
linkage to care facilities and challenges with meeting treatment and transport costs [1, 2, 4].
While many researchers appear to pay much attention about the care obligation to research
participants during trial conduct, less importance is attached to the post-trial period and there-
fore less effort is put in managing this phase of trial conduct [5]. It should however be empha-
sised that trial closure is an important part of the trial and should be managed appropriately.
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Recently, debates regarding post-trial access and post-trial care have emerged, with several
researchers advocating for post-trial care. However, the voices of those most concerned,
including trial participants and researches has not been adequately represented [1].
Existing ethical guidelines stipulate a range of post-trial care obligations for researchers
involved in HIV clinical trials, including the need to ensure continued access to required HIV
treatments, psychosocial support, and other services [6, 7]. This requires appropriate linkage
of trial participants back to adequate services (‘usual care’) once the trial has concluded. Good
practice also includes the provision of trial feedback to participants [8, 9]. There is very little
evidence available however to guide current practice in this area or to determine the adequacy
and appropriateness of existing post-trial guidance, particularly in low income settings [10,
11], with available guidelines being criticized for being generic and providing little detail on
how to adapt and apply such principles into highly diverse local contexts [1, 2, 11]. There is a
call to develop post-trial care guidelines that are flexible and sensitive to local contexts and to
the specific needs of different groups of participants. In line with good research practice and
with the principles of patient and public involvement [12], such guidance should be developed
collaboratively by a range of different stakeholders such as the government, researchers, com-
munities, and research sponsors [13, 14], and implemented in research practice [15].
This article aims to propose and present a model that can guide the post-trial care process
of HIV trial participants. The proposed model is based on findings from a research study that
explored how care is perceived and enacted in HIV drug trial closure in Uganda [16]. The
model, entitled ‘Facilitated Transition’ generates new insights for researchers and other stake-
holders on how to plan and provide holistic and person centred care during closure of clinical
trials involving HIV positive participants in a low income setting.
2. Research methodology
The research aimed to establish an in-depth understanding of the post-trial care phenomenon
amongst participants in HIV drug trials in Uganda. It adopted an interpretive-constructivist
grounded theory approach [17]. The study included participants and research staff from three
HIV drug trials, with one (Trial 2) focusing on HIV prophylaxis while two (Trials 1 and 3)
focused on HIV treatment. Trials 1 and 3 were conducted by the same research institution but
at different sites. Trial 1 was conducted at an urban site, situated in Kampala—the capital city
of Uganda, while Trial 3 was conducted at a peri-urban site, in the Eastern part of Uganda.
Trial 2 was conducted at a peri-urban site in the Western part of Uganda. Table 1 below pro-
vides a summary of the included trials’ characteristics.
2.1 Recruitment and data collection methods
The sample strategy aimed to achieve a balance between geographical sites and participant
gender and was guided by the principle of theoretical saturation. Both purposive and conve-
nience sampling approaches were employed in selecting trial participants and research staff.
The purposive approach enabled us to select eligible trials and research staff in order to include
a variety of different features such as different staff cadres that included research nurses, clini-
cians, study coordinators and those attached to counselling. The convenience sampling
approach enabled us to include trial participants and research staff who were willing and avail-
able to be interviewed. The study included 21 post-trial participants and 22 research staff.
Inclusion of both groups was necessary to enable us to gain a broader understanding of the
post-trial process from the perspectives of the key stakeholders involved and supported data
triangulation. Confidentiality was ensured by having all eligible trial participants contacted by
their former research institutions, to seek their permission to be contacted by the researcher.
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Those who consented were then approached using phone calls or home visits by the first
author. Research staff were approached directly within their institutions, through their super-
visors. All but three participants who were contacted agreed to participate in the research. The
eligibility criteria for the study is presented in Table 2 below.
Data from post-trial participants was collected using in-depth interviews, while a mixture
of Focus Group Discussions (FGDs) and Key Informant Interviews (KIIs) were used to collect
data from research staff. Participants were asked open ended questions about their experiences
of trial closure. All interviews were audio recorded and field notes were taken by the lead
researcher to capture additional information of relevance. Data collection followed the con-
structivist Grounded Theory approach by Charmaz, where initial data analysis informed later
data collection [18, 19]. The first author, who was a PhD student at the time of the research,
administered all interviews. This author was fluent in the two languages (Luganda and
English) in which the interviews were collected, hence there was no requirement to have trans-
lators. All interviews were undertaken in the research clinics which the respective trial partici-
pants had attended. Participants were compensated with refreshments and a sum of
Ugx10,000 (approx. £2.5) mainly to contribute to their transport refund. Data was collected
during October 2014 to August 2015.
Table 1. Characteristics of included trials.
Characteristic Trial 1 Trial 2 Trial 3
Research aim (main
objective)
Tested various second line treatments in
patients who had failed on a first line
regimen in Africa
Evaluated the safety of discontinuing
Cotrimoxazole prophylaxis among adult HIV
infected clients on ART in Uganda
Investigated the ability of three methods to
reduce early mortality among patients
initiating antiretroviral therapy (ART) while
severely immuno-suppressed
The immune/health status
of trial participants at
recruitment
All participants were HIV-positive with
immune suppression (as was defined by
the modified World Health Organisation
(WHO) 2010 criteria1) following first line
treatment failure
All participants were HIV-infected with a
sustained immune restoration (measured as a
confirmed increase in CD4 T-cell count to
250 or more cells/mm3) following ART
All participants were HIV-infected, with
severe immuno-deficiency (CD4 T-cell






Had previous experience Had previous experience No prior experience of specialised HIV care/





No contact retained Participants continued to contact their
former facilities on a three monthly basis for
routine check-ups
Participants had no pre-trial HIV care
providers
Access to HIV care and
treatment during research
All HIV related care and treatment was
received from the research facility
The trial regimen and treatments for
opportunistic infections were provided by
the research facility, while other routine
medications including ART and associated
HIV routine services such as counselling
were obtained from their former care
facilities
All HIV related care and treatment were
provided by the research facility
Presence of a public HIV
care facility attached to
the research institution





1 Modified World Health Organisation (WHO) 2010 criteria for treatment failure included:
• New WHO Stage 4 event (with CD4 < 200 cells/mm3 and viral load (VL) > 400 copies/ml)
• CD4 < 100 cells/mm3, or CD4 fall to pre-treatment baseline or below, or CD4 < 200 cells/mm3 X 2 with previous CD4 > 400 cells/mm3 (with VL > 400 copies/ml)
• VL > 5,000 copies/ml ×2
https://doi.org/10.1371/journal.pone.0250698.t001
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2.2 Data analysis
Interviews were recorded, transcribed, and, where necessary, translated before analysis by the
first author. NVivo 10 software was used to organize and manage the data. Data analysis fol-
lowed a standard grounded theory approach [17, 19]. An initial line by line coding process
enabled an openness for any possible theoretical interpretations from the data. Some initial
codes were conceptual in nature and were later upgraded to theoretical categories. We then
undertook focused coding to elicit more conceptual codes that were representative of the data.
This process eventually led to the identification of concepts that were further transformed into
tentative categories. Further analytical techniques involved memo writing, theoretical sam-
pling, constant comparison, and diagramming. These analytical techniques led the team to
identify a core category ‘Facilitated Transition’ [17, 20], that was developed, through further
analysis, into the Facilitated Transition Model.
2.3 Maintaining rigor
Attention to rigor was achieved through on-going discussions within the research team
regarding each step of the research process and the resultant interpretations from the data
[21]. In addition, we strove to enhance credibility by using verbatim quotes to support our
interpretations of the data and paying attention to disconfirming cases and opposing or diver-
gent views of the participants. Credibility of the main findings was also enhanced as a result of
extensive triangulation of the data (from different sites, different trials and different participant
groups).
2.4 Reflexivity
We took note of possible influences that the researchers’ theoretical and practice perspectives
could have on the research. The first author had previously worked as a research nurse in
Uganda. This had exposed her to some of the concerns that HIV post-trial participants face
during trial closure. Hence, this background had potential to influence her approach to the
research, and her interpretations of the data. We tried to minimize this possible influence
through constant discussions with other team members and careful memoing, a process that
constantly challenged her pre-suppositions.
Table 2. Eligibility criteria.
Considered aspects Eligibility criteria
Trials • Involved HIV positive participants
• Involved an HIV treatment or prevention drug
• Lasted for at least two years
• Was within four to 12 months of trial closure
Post-trial participants • HIV positive
• Participated in a prevention or treatment drug trial
• Participated in the trial for at least six months
• Within three to twelve months of trial exit
Research staff • Worked directly with trial participants
• Was involved in trial closure processes within the past one year
https://doi.org/10.1371/journal.pone.0250698.t002
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2.5 Ethical approval
Ethical approval was received from the University of Nottingham, UK and The AIDS Support
Organization (TASO) Uganda, Research Ethics Committee (REC). The study was registered
with the Uganda National Council for Science and Technology (UNCST), as SS3608. Permis-
sion to conduct the research was granted by the respective research institutions, and written
informed consent was received from all respondents.
3. Findings
This study included a total of 43 respondents from three HIV drug trials. Twenty-one of these
were post-trial participants while 22 were research staff. Of the included trial participants,
seven were from Trial 1, eight were from Trial 2, while six were from Trial 3. The majority of
trial participants (62%) were female. Trial participants were in the age range of 26–59 years,
with the majority (67%) being 40 years and above. Only one participant had attained a univer-
sity degree, and the majority (67%) were below college level, having either stopped at ordinary
or primary levels, or had no education at all. Very few trial participants (14%) were in official
employment, while the rest depended on small scale jobs, subsistence farming, or other sources
of income such as support from families or friends. Ninety percent (90%) of the trial partici-
pants resided in rural or peri-urban settings.
Of the research staff, three were trial coordinators, four were clinicians, five undertook
counselling and home visiting, and 10 were nurses (one of the trial coordinators was also a
nurse). Trial 1 included 15 research staff, Trial 2 included four research staff, and Trial 3
included three research staff. One quarter of the research staff were male. Although we aimed
to have approximately equal numbers of staff per trial, this was not possible due to the diverse
composition of staff in the respective trials, both in cadre and numbers. We also reviewed ethi-
cal documents from two trials (Trials 1 and 2), which included: the general trial protocols, par-
ticipant information documents, informed consent documents, and the trial closure ‘Standard
Operating Procedure’ (SOP) documents, also sometimes referred to as the Close out ‘Manual
of Operations’ (MOP).
3.1 The facilitated transition model: Understanding trial closure as a
process
Below, we describe the main category that was interpreted from the research–the ‘Facilitated
Transition Model’. The model is presented as a whole, followed by a more detailed description
of its distinct phases and how they inter-relate, supported by participant quotes and contextual
narrative.
Our findings revealed that the transition of HIV positive participants from trial healthcare
to non-trial (‘usual’) care facilities was a complex and multi-faceted process that occurred over
time and with specific phases. This ‘transition process’ encompassed the events which
occurred when an HIV positive trial participant, following planned completion of trial partici-
pation, was exited from research and linked back to the public healthcare system, to continue
accessing HIV services. One trial participant referred to this transition as “moving between two
worlds”.
The main events which occurred along the transition process related to trial participants’
care expectations, needs, experiences, and decisions, and to the actions of researchers intended
to facilitate and support them. Our research showed that trial participants moved through 3
phases of the trial closure experience during the transition process, which include: (i) the pre-
closure phase (which represents events or experiences that occurred before the actual trial
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closure but that influenced the post-trial care experiences), (ii) the trial closure phase (which is
the active phase of the closure in which trial participants were prepared and exited from the
trials), and, (iii) the post-trial phase (which represents events that occurred after trial partici-
pants had been exited from the trials until 12 months later). These phases are demarcated by
time points that reflect how the transition process evolved, proceeded and concluded. Our
findings also identified facilitative actions and strategies that were or could be implemented at
each stage to support the transition process. These include: (i) planning for post-trial care (in
phase 1), (ii) providing emotional and practical support (in phase 2) and (iii) providing psy-
cho-social support (in phase 3). The process and its phases are depicted in Fig 1, in a model of
‘Facilitated Transition’, followed by a description of each phase of the model in turn.
3.2 Pre-closure phase
The pre-closure phase starts before or during planning of the trials up to three months before
the actual exit of the participant from the trial (Tθ -T-3). Several contextual factors that existed
prior to trial participation were found to influence how participants reacted to the closure and
how they made decisions about post-trial care. These factors include those related to (i) indi-
vidual participants and (ii) those related to the Ugandan health care structures.
3.2.1 Personal circumstances. Personal factors such as ongoing ill health and poverty,
and trial participants’ experiences at the end of previous trials in which they may have partici-
pated influenced their care needs, expectations and experiences during the closure of the cur-
rent trial. For example, participants with ongoing health issues (such as opportunistic
infections) during trial closure were worried about how they would receive care after they left
research, and these worries were exacerbated for those living in poverty. In addition, some par-
ticipants had previous experience of being involved in research, and their previous experiences
influenced their expectations of post-trial care in the current trial (for example if they had pre-
viously been given money or other benefits):
. . . because I will refer so much to the other one (trial) . . .. . . while exiting us, they also gave
us some money. Yes and now this one, they just exited us, and only gave us transport. So now
that is why I have told you that I will insist on that, to show you that we didn’t receive any
money as such, yet in the other one people were many in the FX study because there was good
money. But this one had no money as such.
(Baker, Trial 2)
3.2.2 Structural factors. Trial participants’ perceptions and experiences of previous
healthcare delivery in Ugandan facilities were also found to influence how they reacted to trial
closure. In the current study, a strongly held perception of ‘poor’ quality of care in the Ugan-
dan public healthcare facilities caused fear and tension amongst trial participants as they
reflected on where they would seek care after the trials ended. Hence, inequalities in care pro-
vision between research facilities and the public health care facilities in Uganda was a contrib-
uting factor to negative emotions among trial participants during trial closure.
When we were brought from there (the former care sites), my understanding was that they
have removed me from that place because it was no longer capable. So when you get me from
there and you bring me here and you send me back after giving me some treatment, and you
send me back there, I think I cannot be contented. Why, because you got me from there and
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brought me, now again you have completed the research and you are taking me back, it
means that I may go back to the same situation as I was.
(Joel, Trial 1)
3.2.3 Planning post-trial care. We established that the pre-closure phase involved activi-
ties undertaken or required to facilitate proper preparation of trial participants for trial closure.
This phase was generally guided by policies on post-trial care that clarify the minimum post-
trial care expectations from researchers. During this pre-closure phase, a key factor thought to
facilitate post-trial care was early discussion about post-trial care plans (where trial participants
were informed about the trial closure processes from the start of the trial). Discussions of
when the closure will occur, how participants will be exited from the research, where they will
be linked for post-trial care, how trial drugs will be accessed after the trial, and when/how trial
results will be disseminated, were made. This activity helped to psychologically prepare the
participants for trial closure.
Trial closure starts at the beginning of the study apparently. Because as we start the treatment
of patients, we go through the screening, we go through the enrolment, we see them settle in,
we prepare them or we tell them that there is time when the study will end so that as we start,
as they settle in, they know that there is time and the trial will end. So, by the time we get to
the closure, they are already into closure.
(Joy, counsellor/health visitor/community mobiliser)
Fig 1. Model of facilitated transition.
https://doi.org/10.1371/journal.pone.0250698.g001
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Policy guidelines were a useful tool for guiding researchers on post-trial care preparation.
Ethical documents such as study protocols, informed consent forms, and trial closure/exit doc-
uments were among the documents that contained information that guided trial closure
processes.
A clinical summary report will also be the referral form. (This) will be produced in triplicate
by the data manager at each site. One copy—kept by the participant, one—taken to the ART
provider (referral letter) by the participant, one kept in the participant’s file.
(MOP, Trial 2)
3.3 Trial closure phase
The trial-closure phase describes events that occurred around the point of trial closure. It
included active trial closure activities such as psychological preparation, exiting, and linking
trial participants to post-trial care facilities. This phase began three months prior to the
planned exit of a participant from the clinical trial until three months after the exit (T-3-T+3).
It was reported that the intensive preparation for trial closure started on average three months
to the planned closure, a period which marked off the trial closure phase as reflected on the
Facilitated Transition model.
The period (of preparing for trial closure) is inbuilt in our community engagement process, so
I don’t want to say three months before the trial ends or six months. It is inbuilt. [. . .] So our
post-trial engagement does not start say, when we have seen the last volunteer, its inbuilt we
share it, but the bridging activities that take us between when people are seen last for their
trial participation and when the results are out, and what happens beyond the results are out
is what I actually I would say begins three months before the end of the trial.
(Bernard, community liaisons officer)
A range of needs were reported among trial participants during the Trial–closure phase,
which involved both emotional and practical needs.
3.3.1 Emotional needs. Participants experienced multiple emotions resulting from the
trial closure and concerns about how to access care afterwards. The main factors that influ-
enced participants’ emotional reactions included: the loss of quality care and valued relation-
ships in research settings, the need for recognition (compensation) for their contributions in
research, worry about future care after leaving research, fear of side effects from trial interven-
tions, and the need to receive feedback on trial outcomes.
What I felt as for me was that we were going to miss the treatment we were receiving from
here. Because at health facility Y, sometimes there is no medications for treating other illnesses
you may suffer from and so you have to buy that medication, yet here we would get it.
(Abdu, Trial 2)
The worries about access to post-trial care were generally associated with the perceived
poor healthcare in the Ugandan public healthcare facilities. Hence, participants reported con-
cerns about how best to find alternative care facilities and how to link to them. Some partici-
pants (such as those in Trial 1) had left their previous ‘usual’ care facilities when they joined
the HIV drug trials while others (from Trial 3) had no HIV care experience prior to taking
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part in the trials. These groups of participants were now required to identify suitable healthcare
facilities for continuation of HIV care and treatment. The good care experiences in the
research centres coupled with perceptions about, and experiences of, poor care in the public
healthcare facilities influenced how trial participants made choices of where to seek post-trial
care.
The care I got there (in research), it was just enough. I thought I am not going back to that
place (pre-trial care facility), I have to go back to site A. Yes, the care and ok the distance also,
but the care most.
(Janet, Trial 1)
3.3.2 Practical needs. Where new facilities were identified, participants also cited chal-
lenges in reporting to them, in terms of the complex procedures required for registering into a
new facility. They reported this process as inconvenient and difficult and expressed a desire to
be supported by the research team, to be assisted to register.
So in order to make it easy for us, they would do the same thing. They would get a person with
their referrals and take him/her back to facility D and they open for you another file. So you
are not disturbed. . .
(Sumin, Trial 1)
3.3.3 Emotional and practical support. To facilitate the trial closure phase, researchers
engaged in offering a range of emotional and practical support strategies to address the care
needs of the participants. The support provided generally included counselling and psycholog-
ical preparation, providing guidance on where to seek post-trial care and linking trial partici-
pants to post-trial facilities through referral.
So the linkage is providing them with a referral form with the details of their clinical picture
which they deliver to the service provider and then it gets filed in their records the other side.
(Ivan, trial coordinator)
3.4 Post-trial phase
The post-trial phase describes events which occurred after a trial participant has been exited
from the trial and linked to a new facility where they would continue to access HIV care. This
phase starts approximately three months following trial closure and continues up to 12 months
later (T+3-T12).
. . .. there is that extra follow-up that may be done probably at 90 days, but continually it
poses a challenge especially when finances have to be incurred.
(Elhana, nurse)
The post-trial phase illuminates how HIV positive trial participants adapted to the post-
trial situation, whilst receiving HIV care and treatment within the Ugandan public healthcare
system. Although trial documents were generally silent on most aspects of this phase,
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researchers and trial participants recognised the need for supporting HIV positive post-trial
participants during this phase. A number of psychosocial and socio-economic factors influ-
enced trial participants’ care needs, expectations and experiences during the post-trial phase.
3.4.1 Psychosocial needs. The psychosocial concerns that arose following participants’
exit from HIV trials included fear of HIV stigma (since non-trial care facilities did not provide
as much privacy as research institutions) and fear of poor healthcare (including overcrowding
in the facilities, lack of privacy, and poor time management), and specific concerns about how
their individual healthcare needs would be met (such as accessing routine HIV medications
and treatments for opportunistic infections). Trial participants also reported negative staff atti-
tudes (e.g. rudeness) which affected clinic attendances.
And I went and informed them ‘I am having headache,’ but it was not a clinic day, and I
informed them I was having headache but they never gave me any medications, not even
Panadol, in fact I went away crying.
(Brenda, Trial 2)
In addition, some participants were concerned about the possibility of side effects resulting
from trial interventions, and wished to be informed of any plans of follow up and monitoring
them after leaving the trials.
Because the other side (post-trial care facility), it is just a matter of presenting your. . ., may be
your book and they write down and they send you to the pharmacy and they pick up your
medication, but they cannot know the changes which is taking place within you. So the first
people (researchers) they are the ones who are good whereby if you have any problem you can
call them and you can go and they try to examine you again and see what is going on.
(Wilberforce, Trial 3)
3.4.2 Socio-economic needs. In terms of socio-economic concerns, participants reported
experiencing significant challenges in meeting the financial burden of accessing care (for
example transport and treatment costs), after leaving the trials. Those with ongoing ill health
problems were affected more significantly by the transition as these were unlikely to be work-
ing yet suddenly required additional finances (e.g. to buy medications or had specific food
requirements).
. . .we have to look for money for transport to fetch medication. And when I fail to get it, I call
them (research staff) and I request them to help me with money to go and I collect the
medication.
(Ruth, Trial 1)
3.4.3 Psychosocial support. A number of measures that are required to support trial par-
ticipants during the post-trial phase were proposed to enable them to cope with both their psy-
chosocial and economic needs. The supportive measures included; establishing mechanisms to
ensure and check that post-trial participants had successfully linked to alternative care facilities
and are receiving appropriate treatments, providing continued psychological support, material
and financial support, and monitoring for possible side effects. Providing such support
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required continued engagement of research staff and other stakeholders with the participants
during the post-trial phase.
I believe we are supposed to be following them up, to see how they are coping up, to see the
challenges they are facing, and like these Trial 3 patients that we recruited with low CD4s, to
find out may be if they have increased, they are rising up, to see generally how they are
improving.
(Favour, Counsellor/home visitor)
However, findings indicated that in current practice, there was very little engagement of
researchers in the post-trial phase, despite this being recognised as a very important part of
trial care.
It is really very important though we don’t actively do it, post follow-up. Because when they go
back to their mother clinics, a lot of things change, it is like transitioning. So if you are transi-
tioning, you need to be followed up until you settle in properly.
(Charlotte, counsellor/home visitor)
In general, the lack of post-trial care was blamed on inadequate policy guidance for
researchers in terms of how to support this phase of the trial. It was felt that the existing guide-
lines lacked detail on important aspects of post-trial care which became a challenge for
researchers to plan for and implement them.
And then, the other thing we have to put into mind is when you are budgeting, you have bud-
geted for the study up to the exit, up to the closure. So you don’t have more funds to cater for
people after this time, may be even the staff have been employed up to that time. All these
things keep, really tie us. [. . .] So even if you wanted, really you can’t.
(Destiny, nurse)
The participants recommended that policy makers include post-trial care into their guide-
lines to make it mandatory for the researchers to provide post-trial support.
So I would recommend that it is put into policy that every trial conducted, especially clinical
trials conducted, they should do a post-trial assessment to know how their patients are doing.
(Alloy, trial coordinator/nurse)
If it is an obligation or if it is a policy of an institution, then they can add it (post-trial follow-




The model presented in this paper shows that clinical trial closure is a complex process for
HIV positive participants in Uganda, and can be conceptualised as having 3 different phases,
each with a range of emotional, socio-economic and practical needs requiring different sup-
port strategies from trial staff. The model is supported by a recent study (albeit in a different
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context) that similarly reported emotional and psychosocial concerns as negative trial-closure
outcomes [1]. In line with Cho and others [6], our findings emphasise the importance of pro-
viding care and support to trial participants to ensure a smooth transition from research to
non-research (‘usual’) care.
In this study, both research staff and participants expressed a strong need for a more facili-
tated approach to the trial closure process, in terms of supporting participants to make the
transition back to usual care facilities at the end of a trial and maintaining contact to ensure
queries around side effects and infromation around trial outcomes could continue to be
shared. The ‘Faciltated Transition’ model describes key facilitation/care strategies that could be
applied during each of the three phases, in order to meet the post-trial participants’ care needs.
The care needs of post-trial participants varied depending on individual circumstances such as
health status, economic status, and available supportive structures, thereby requiring a case by
case approach to post-trial care, while trying to observe the general ethical guidelines. Hence,
the Facilitated Transition Model depicts a person centred approach, and considers the need for
ethical practice within a flexible context-based framework [22]. The proposed model alligns
with the Ethics of Care theory, that suggests a felxible-person centred approach to implementa-
tion of research ethics and this approach has been recommendd by several authors [23–25].
The pre-trial phase sets the pace for post-trial care by identifying trial participants’ expecta-
tions of post-trial care and is the beginning of preparation for trial closure. It is recommended
that post-trial care activities and outcomes (such as potential harms) be disclosed to the partici-
pants before consent to participate, to facilitate the informed consent process [1]. Our research
established that policies play a significant role at the pre-trial phase, to guide researchers on
what is expected of them in regards to post-trial care, a finding that is supported by other
researchers [26, 27]. As Slack recommends, the guidelines should be comprehensive enough to
include activities that will be done to meet the post-trial needs of the participants [11].
The trial-closure phase highlights the main fears and concerns of trial participants associ-
ated with leaving trial-related healthcare and finding suitable alternatives. The psychological
concerns that arise within the trial-closure phase mainly relate to the loss of the quality care in
research related facilities which cannot be matched with that in the public sector and have
been reported by other authors [1, 2]. Our study further established that post-trial participants
go through a financial burden associated with continued access to treatments especially for
opportunistic infections (and especially among those with low immunity). A recent systematic
review reported that the psychological effects associated with the loss of care benefits from
research can affect the integration of post-trial participants into the public services [3]. These
findings suggested the need to support trial-participants during the transitioning from
research to non-research care. Several forms support, including psychological, financial and
material support have been proposed in the model of Facilitated Transition and also recom-
mended by other authors [28, 29]. In addition, our study reported that participants found a
challenge of locating and reporting to new service providers and suggested that the process of
linking to care needed to a more active approach from the trial researchers. Although limited
research exists in the area of linkage to HIV post-trial care, several studies undertaken in the
area of HIV testing have recommended support of individuals by healthcare personnel as a
suitable approach in enabling successful linkage of HIV positive individuals to care after HIV
testing [30–33].
The post-trial phase is the period where trial participants adjust and get integrated into the
public healthcare system following trial exit. Participants report unique needs during this
phase that may affect their health and wellbeing, including access to HIV treatment and pre-
vention drugs, having to deal with the routines of the public healthcare system which are
largely unfavourable and looking for financial wellbeing. The model of Facilitated Transition
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suggests that linkage to HIV post-trial care is not a one off event and reccomends the need for
supporting trial particpants during the post-trial phase, through a follow up mechnism and
continous engagement by research staff (and other stakeholders), to enable them to get well
established into the ‘new’ healthcare system. These recommendations are interndem with
those of Cho, Danis, & Grady [6] that underscore the need for supporting trial participants
beyond the study period.
A cross-cutting concern across the whole transition journey is the lack of guidelines in sup-
port of post-trial care. It was reported that limited support was provided in the post-trial
phase, as most activities were not actively planned for by the researchers. The trial documents
that were reviewed as part of the study found that they lacked guidance on some of the impor-
tant post-trial care aspects, as observed by other researchers [11, 15]. Our study reccomends
the need for policies on post-trial care to be strengthened, by highlighting the important post-
trial care requirements and enforcing them in research practice.
4.1 Transferability of the conceptual model
The model of Facilitated Transition is primarily intended to guide the practice of closure of
HIV drug trials invoving HIV postive individuals in Uganda, by providing flexible guidelines
which can be applied to different HIV drug trial contexts and geographical settings in Uganda.
These guidelines can however be applicable in other situations such as HIV drug trial closure
in other low income settings, transitioing of post-trial participants with other chronic illnesses
such as cancer, transitioning of individuals hospitalised for long periods and re-establishing
into the community/other healthcare settings, and settling of other groups of individuals in the
community e.g. from prisons.
4.2 Limitations
This was a single qualitative study that was conducted only in one country (Uganda) which
limits generalizability of the research findings beyond the studied context. Additionally, this
study presented potential for selection bias since we used researchers to identify participants
who would be accessible and willing to participate and recall bias given that it was undertaken
retrospectively with some participants being interviewed close to 12 months following trial
exit. A larger prospective study on a similar population would limit the above biases and
potentially improve understanding of the studied phenomenon.
4.3 Conclusions
This article expands on the understanding of trial closure and post-trial care in HIV drug trials
involving HIV positive individuals in low income settings, by describing trial closure as a pro-
cess rather than a one-off event. The Facilitated Transition model explains the process of tran-
sitioning from HIV research to ‘usual care’ facilities and offers guidelines on a person-centred
approach to post-trial care. By illustrating the concerns and needs of the participants, and sug-
gesting possible support approaches to address these, the model can thus be useful in the plan-
ning and provision of post-trial care for HIV positive trial participants in Uganda and related
settings. This approach is likely to result into favourable health outcomes for the participants.
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